| Autor: |
Hoffman MK; Department of Obstetrics and Gynecology, ChristianaCare, Newark, DE 19718, USA., Kitto C; Department of Obstetrics and Gynecology, ChristianaCare, Newark, DE 19718, USA., Zhang Z; Department of Obstetrics and Gynecology, ChristianaCare, Newark, DE 19718, USA., Shi J; Walker Bioscience, Carlsbad, CA 92009, USA., Walker MG; Walker Bioscience, Carlsbad, CA 92009, USA., Shahbaba B; Departments of Statistics and Computer Science, University of California Irvine, Irvine, CA 92697, USA., Ruhstaller K; Department of Obstetrics and Gynecology, ChristianaCare, Newark, DE 19718, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2024 Jul 09; Vol. 14 (14). Date of Electronic Publication: 2024 Jul 09. |
| DOI: |
10.3390/diagnostics14141462 |
| Abstrakt: |
The AVERT PRETERM trial (NCT03151330) evaluated whether screening clinically low-risk pregnancies with a validated maternal blood biomarker test for spontaneous preterm birth (sPTB) risk, followed by preventive treatments for those screening positive, would improve neonatal outcomes compared to a clinically low-risk historical population that had received the usual care. Prospective arm participants with singleton non-anomalous pregnancies and no PTB history were tested for sPTB risk at 19 1/7 -20 6/7 weeks' gestation and followed up with after neonatal discharge. Screen-positive individuals (≥16% sPTB risk) were offered vaginal progesterone (200 mg) and aspirin (81 mg) daily, with twice-weekly nurse phone calls. Co-primary outcomes were neonatal morbidity and mortality, measured using a validated composite index (NMI), and neonatal hospital length of stay (NNLOS). Endpoints were assessed using survival analysis and logistic regression in a modified intent-to-treat population comprising screen-negative individuals and screen-positive individuals accepting treatment. Of 1460 eligible participants, 34.7% screened positive; of these, 56.4% accepted interventions and 43.6% declined. Compared to historical controls, prospective arm neonates comprising mothers accepting treatment had lower NMI scores (odds ratio 0.81, 95% CI, 0.67-0.98, p = 0.03) and an 18% reduction in severe morbidity. NNLOS was shorter (hazard ratio 0.73, 95% CI, 0.58-0.92, p = 0.01), with a 21% mean stay decrease among neonates having the longest stays. Sensitivity analyses in the entire intent-to-treat population supported these findings. These results suggest that biomarker sPTB risk stratification and preventive interventions can ameliorate PTB complications in singleton, often nulliparous, pregnancies historically deemed low risk. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
